A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
about
The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical TrialsSafety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trialsEffectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic PatientsCardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-AnalysisDipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trialsComparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysisCost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications.Cardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review.Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparisonEffectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE)Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options.Effectiveness and Tolerability of Second-Line Therapy with Vildagliptin Versus Other Oral Agents in Type 2 Diabetes (EDGE): Post Hoc Sub-Analysis of Bulgarian Data.Observational and clinical trial findings on the comparative effectiveness of diabetes drugs showed agreement.Effectiveness and tolerability of second-line therapy with vildagliptin versus other oral agents in type 2 diabetes (EDGE): post-hoc subanalysis of the Belgian data.Enhanced glycemic control with combination therapy for type 2 diabetes in primary care.Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease.A 16-week study to compare the effect of vildagliptin versus gliclazide on postprandial lipoprotein concentrations and oxidative stress in patients with type 2 diabetes inadequately controlled with metformin monotherapy.Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin.Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice - study rationale and protocol of DIALOGUEAddition of sulphonylurea to metformin does not relevantly change body weight: a prospective observational cohort study (ZODIAC-39).A systematic literature review on the efficacy-effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs.A randomized controlled clinical trial of vildagliptin plus metformin combination therapy in patients with type II diabetes mellitus.Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin.Review of the safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.Choosing a gliptin.The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.The design of the liraglutide clinical trial programme.Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis.Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety.The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis.Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials.Composite endpoints in trials of type-2 diabetes.Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.The long-term efficacy and safety of DPP-IV inhibitors monotherapy and in combination with metformin in 18,980 patients with type-2 diabetes mellitus--a meta-analysis.Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.
P2860
Q26748870-21A5D24A-54FB-48E7-947B-E38E203CB614Q27022613-44AB1391-93BD-4BD1-BF76-2004F398E879Q28067209-DA21DE5B-681E-4C6C-B504-D1D42A2AA563Q28071764-96739BD2-9346-4A71-87DE-956A99B31E5CQ28294225-FD11A697-7369-4EF4-A480-84AD06937EB7Q28546797-20D126EC-8056-4E0F-A2BA-9623078193B5Q30234836-C33FC186-B57A-4A8A-A329-6AC07E82AB48Q30241808-75C39427-0B10-4B8A-82F1-ECFA18A62FC5Q30249371-D3444C1F-56B1-44B6-BC7D-62C071573B4FQ33710159-96AF72FE-0401-48B3-A12F-F5F4880D927EQ33785197-E4EFD8D1-12C7-41CE-B7AB-2BE4016D3BCDQ34507122-9D35B645-0BD0-4631-8FAB-C145F3915540Q34563587-B82C7D69-2C7F-4E46-889D-E4B433E9215EQ34726395-BAF3EF42-34BB-445E-8788-9ACB4C41E92CQ35146648-82DCC126-DBD4-4CB5-8416-8C5538266FF9Q35167496-A1D57534-F6C9-429E-9ABE-509E7CD5CE2AQ35214435-DCA77DFD-5259-4B39-B298-1A6674ADC6CBQ35717211-68CFDCB3-3711-4A60-862F-03AB81FDF1F4Q35844788-6C97B633-9587-4CB5-B392-D1EFC37EAE4EQ36428052-112ABC42-7A0F-4A53-95FB-E3E6D86ED26FQ36510353-32C1DA46-3906-4868-90C5-F8268D661F33Q37456636-2DCF7BB4-C55E-4CBE-88D4-43FE40133AA2Q37610459-A992730B-3F7D-40CF-A09B-7648738F521EQ37652091-C63871DA-8CA0-4C08-AA7C-999F4E35EA1FQ37825941-8CF8CA04-8E4B-4985-8E03-8B9CE7F9285EQ37890793-DF8017CF-CE98-4F12-85A0-AEFB1655D40CQ37949599-19640831-C34B-4F5F-BE6C-EBB6362312CFQ37970749-519A8569-1526-4287-9A82-01B413F0F36EQ37991385-E7127B78-D25C-4805-B09E-634857B663D1Q37992253-7295CDD7-1A86-447F-B343-B809B4B5F258Q38001085-C76FE3A2-E2D6-4618-8D43-06761F9B64C6Q38004088-AD8F435B-CB7A-41FA-8D54-BB54C88F2FA7Q38100678-F67A8B93-4DD1-436A-B063-3A8800D089E4Q38126945-34CD338D-0235-40CB-9652-6669858776EDQ38137027-50CB5198-2EE7-4423-8368-71650044BB4DQ38152405-7E33E54A-858B-4D22-9589-8BDAC86C9B84Q38154679-441AAB57-FC18-46A0-A1DB-1BD14F0D3160Q38163071-86B3194A-7F75-4A9F-9195-F566B30C6262Q38196747-73240C39-8B0B-4931-814F-E78D378D3062Q38212472-BA2FF701-569C-4366-811D-85EED09BFD66
P2860
A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
A comparison of efficacy and s ...... : a 52-week, randomized study.
@en
A comparison of efficacy and s ...... : a 52-week, randomized study.
@nl
type
label
A comparison of efficacy and s ...... : a 52-week, randomized study.
@en
A comparison of efficacy and s ...... : a 52-week, randomized study.
@nl
prefLabel
A comparison of efficacy and s ...... : a 52-week, randomized study.
@en
A comparison of efficacy and s ...... : a 52-week, randomized study.
@nl
P1433
P1476
A comparison of efficacy and s ...... : a 52-week, randomized study.
@en
P2093
J-F Gautier
P304
P356
10.1111/J.1464-5491.2010.02938.X
P577
2010-03-01T00:00:00Z